• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Healthcare·CRW.L
Share

Craneware plc Stocks

£ 1300Last Updated 21.08.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

£ 607.09M

£ 1300
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Craneware plc, with its associated entities, is dedicated to creating, distributing, and maintaining cutting-edge software applications tailored for the U.S. healthcare industry. Its extensive suite of products is designed to streamline and improve a wide array of operational functions for healthcare organizations. Among its flagship offerings is the Chargemaster Toolkit, an automated, cloud-hosted platform for charge master administration, crucial for enabling providers to achieve optimal and legitimate revenue reimbursement. Trisus Supply facilitates the identification and resolution of data inconsistencies between disparate systems. The Physician Revenue Toolkit, a Software-as-a-Service (SaaS) solution, empowers the oversight of physician group performance indicators, billing rates, procedural codes, relative value units, and fee schedules. Complementing these are Reference Plus, another SaaS tool for comprehensive chargemaster analytics, and Pharmacy ChargeLink, engineered to bolster charge capture, pricing strategies, and cost control within pharmacy operations. Furthermore, the company offers integration software that autonomously uploads chargemaster modifications to patient billing systems, thereby ensuring billing precision. The Trisus Pricing Analyzer, a SaaS application, streamlines the pricing model development process. Extending its capabilities, Craneware delivers tools for regulatory adherence and financial oversight: InSight Medical Necessity, a SaaS solution for validating the medical necessity required by U.S. payers and for creating advance beneficiary notices; Trisus Claims Informatics, a program that automates the review of claims and coding; and InSight Audit, a browser-based audit management application for healthcare entities to handle governmental and commercial examinations. Additionally, the firm presents Trisus Healthcare Intelligence, a platform for cost analysis and resource optimization; solutions for pricing transparency; and InSight Denials, which facilitates the analysis, tracking, trending, and reporting of denial data, further supported by appeals management services. Beyond its software offerings, Craneware provides comprehensive client success management, specialized consulting, and an array of professional services. The organization also oversees its own sales, marketing efforts, and continuous product and software innovation. Founded in 1999, Craneware plc has its corporate headquarters situated in Edinburgh, United Kingdom.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of CRW.L is 2536 and suggests 95.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.08.2026 03:44

Trump has threatened Canada with new 50% tariffs. Who stands to lose?

25.08.2026 02:34

Nebius Raised $5.75 Billion for Data Centers and AI Through a Bond Offering

25.08.2026 01:33

The Ministry of Finance did not make any new promises to the market regarding the buyback of government debt. Will its $1 trillion in reserves help?

24.08.2026 23:52

Insiders bought $15 million worth of Alibaba stock after the crash. Should you follow their lead?

24.08.2026 23:04

"The Qualcomm Challenge": What Does Xiaomi's Release of Its Own New Mobile Processor Mean?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026